— Know what they know.
Not Investment Advice
Also trades as: CRY (NYSE) · $vol 4M

AORT NYSE

Artivion, Inc.
1W: +2.9% 1M: +15.2% 3M: -30.9% YTD: -41.3% 1Y: -15.9% 3Y: +53.6% 5Y: +2.3%
$27.01
+0.91 (+3.49%)
 
Weekly Expected Move ±6.8%
$22 $24 $25 $27 $29
NYSE · Healthcare · Medical - Devices · Alpha Radar Buy · Power 68 · $1.3B mcap · 46M float · 1.73% daily turnover · Short 79% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$1.3B
52W Range19.16-48.25
Volume415,401
Avg Volume798,139
Beta1.25
Dividend$0.12
Analyst Ratings
10 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEOJames Patrick Mackin
Employees1,800
SectorHealthcare
IndustryMedical - Devices
IPO Date1993-02-12
1655 Roberts Boulevard N.W.
Kennesaw, GA 30144
US
770 419 3355
About Artivion, Inc.

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Recent Insider Trades

NameTypeSharesPriceDate
GREEN ANDREW M M-Exempt 14,001 $18.44 2026-06-11
GREEN ANDREW M S-Sale 14,001 $20.71 2026-06-11
GREEN ANDREW M M-Exempt 30,000 $11.03 2026-06-11
GREEN ANDREW M S-Sale 30,000 $20.69 2026-06-11
GREEN ANDREW M M-Exempt 14,001 $18.44 2026-06-11

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms